IMPACT, The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Deakin University, PO Box 281, Barwon Health, Geelong, Vic, 3220, Australia.
Barwon Health, University Hospital, Geelong, Australia.
BMC Musculoskelet Disord. 2021 Feb 11;22(1):172. doi: 10.1186/s12891-021-04042-w.
Anticonvulsant use has been linked to bone deficits in specific patient populations. We studied the association between anticonvulsant use and bone health in a population-based sample of men and women.
Data from 926 men (24-73 yr) and 1070 women (21-94 yr) participating in the Geelong Osteoporosis Study were included. Bone mineral density (BMD, g/cm) of the PA-spine and total hip was measured using dual-energy X-ray absorptiometry (Lunar). Bone quality was determined using quantitative heel ultrasound (QUS). Anthropometry was conducted and socioeconomic status was determined. Medication and lifestyle information was obtained via questionnaire. Linear regression was used to test associations between anticonvulsant use and bone health before and after adjustment for potential confounders.
Seventeen (1.8%) men and 20 (1.9%) women reported anticonvulsant use. In men, anticonvulsant users had 9.1% lower adjusted mean BMD at the spine and hip compared to non-users. Body mass index was an effect modifier at the spine. Anticonvulsant users also had 1.8% lower speed of sound (SOS), 10.6% lower broadband ultrasound attenuation (BUA) and 13.7% lower stiffness index (SI) compared to non-users. In women, BMD tended to be lower at the hip compared to non-users as with the bone quality measure, BUA. No significant associations were observed at the spine or the other bone quality measures, SOS and SI.
Our data suggest that bone quantity and quality, assessed using BMD and QUS, are lower for men and possibly women who use anticonvulsants. While further exploration into potential mechanisms is needed, our findings suggest that monitoring bone health among users of anticonvulsants is warranted.
抗惊厥药物的使用与特定患者群体的骨骼缺陷有关。我们研究了人群中男性和女性中抗惊厥药物的使用与骨骼健康之间的关系。
研究纳入了参加 Geelong 骨质疏松研究的 926 名男性(24-73 岁)和 1070 名女性(21-94 岁)的数据。使用双能 X 射线吸收法(Lunar)测量 PA 脊柱和全髋关节的骨矿物质密度(BMD,g/cm)。使用定量足跟超声(QUS)测定骨质量。进行人体测量学检查并确定社会经济地位。通过问卷获得药物和生活方式信息。线性回归用于测试抗惊厥药物使用与骨健康之间的关联,在调整潜在混杂因素之前和之后进行测试。
17 名男性(1.8%)和 20 名女性(1.9%)报告使用抗惊厥药物。在男性中,与非使用者相比,抗惊厥药物使用者脊柱和髋部的调整平均 BMD 低 9.1%。体质指数是脊柱的一个效应修饰因子。与非使用者相比,抗惊厥药物使用者的声速(SOS)也低 1.8%,宽带超声衰减(BUA)低 10.6%,刚度指数(SI)低 13.7%。在女性中,与非使用者相比,髋部的 BMD 趋于更低,与骨质量测量的 BUA 一样。在脊柱或其他骨质量测量,SOS 和 SI 方面未观察到显著关联。
我们的数据表明,使用 BMD 和 QUS 评估的骨量和骨质量,男性和可能的女性抗惊厥药物使用者较低。虽然需要进一步探索潜在机制,但我们的研究结果表明,有必要对抗惊厥药物使用者的骨骼健康进行监测。